Volume 73, Number 8 (November 2015)                   Tehran Univ Med J 2015, 73(8): 584-591 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sadighi S, Kamranzadeh H, Jahanzad E, Vaziri S. Androgen receptor expression on breast cancer cells: a clinicopathologic and survival study . Tehran Univ Med J. 2015; 73 (8) :584-591
URL: http://tumj.tums.ac.ir/article-1-6965-en.html

1- Department of Internal Medicine, Cancer Research Center of Cancer Institute of Iran, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
2- Department of Internal Medicine, Blood, Oncology and Stem cell Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. , dr.kamranzadeh@gmail.com
3- Department of Pathology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
4- Department of Pathology, Cancer Research Center of Cancer Institute of Iran, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Abstract:   (2080 Views)

Background: Breast cancer is the most common cancer in women around the world. It has been known for over a century that androgens and androgen receptor (AR) play a role in normal and neoplastic breast cells. The aim of this study was to determined the AR expression on tumor cells and its correlation with other prognostic and predictive factors as well as contribution of AR in patients overall survival (OS) and disease- free survival (DFS). Methods: This retrospective cross-sectional study performed on 189 patients who referred to Medical Oncology Ward of Cancer Institute, Tehran University of Medical Sciences, from April 2007 to February 2010. We performed an immunohistochemistry study for AR (AR441 clone, Dako, Germany) (10% cut-off point) and Ki-67 MIB-1 clone, Dako, Germany) on paraffin embedded blocks. Other data were extracted from patients’ documents. Results: Overall, AR expression was 49.1%. Mean age of the patients with and without AR was 47.86 and 48.49 years, respectively. AR positive tumors presented more in stage I/II than III/IV (P=0.02) and AR were more positive for estrogen receptor positive, lower grade of tumor (grade I/II versus III) and lower Ki-67 (P=0.01). AR positivity had neither correlation with progesterone receptor, HER2/neu, P53 expression or menopausal status. OS and DFS were higher in AR positive patients but did not reach statistical significance. In triple-negative breast cancer (TNBC) group, 25% of tumors showed AR expression. AR had non-significant positive correlation with OS in TNBC cancer patients. OS and DFS had significant statistic positive correlation with ER, PR and stage regardless of AR status. Conclusion: Based on this study, although androgen receptor expression showed correlation with other prognostic factors for survival in patients, we didn’t find statistically significant independent relationship between AR and overall survival in patients. As far as there isn’t any targeted therapy for triple-negative breast cancer (TNBC), prospective basic and clinical studies regarding AR inhibitors in the treatment of TNBC seems to be logical and valuable.

Full-Text [PDF 325 kb]   (636 Downloads)    
Type of Study: Original Article |

Send email to the article author


© 2017 All Rights Reserved | Tehran University Medical Journal TUMS Publications

Designed & Developed by : Yektaweb